ClinicalTrials.gg
RecruitingNCT06037434Updated Sep 15, 2023

Study of Innovative Drug Treatment Therapy for Pediatric Mitral Regurgitation

An observational study in Congenital Mitral Insufficiency, sponsored by China National Center for Cardiovascular Diseases. Recruiting at 1 site in China. Open to participants aged Up to 14 Years. Per ClinicalTrials.gov, last updated 2023-09-15.

Sponsored by China National Center for Cardiovascular Diseases · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2024, 2 years 3 months ago, but the record still lists the study as recruiting.
  • Started Apr 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
122
Ages
Up to 14 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies in Heart Defects, Congenital by China National Center for Cardiovascular Diseases — 5 open to participants now, 6 under way, none of them phase 3. Heart Defects, Congenital · China National Center for Cardiovascular Diseases.

Started
2022
with 5 others
Observational
8 of 10
5 open now
Registered
3rd of 10
by date

Among the 10 studies in Heart Defects, Congenital by China National Center for Cardiovascular Diseases, this one is one of 6 that started in 2022, is one of 8 observational ones, and was the 3rd registered.

Heart Defects, Congenital

992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.

Browse Heart Defects, Congenital studies →

Open to participants now

5 of the 10 studies in Heart Defects, Congenital by China National Center for Cardiovascular Diseases are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.

This study: Up to 14 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Heart Defects, Congenital by China National Center for Cardiovascular Diseases, or all of them as a file.
02

Study summary

The goal of this observational study is to compare the safety and effectiveness of a modified drug therapy with traditional drug therapy in pediatric patients with mild to moderate mitral valve regurgitation.

The main questions it aims to answer are:

  • Can a modified drug therapy improve both left ventricular and mitral valve function in pediatric patients with mild to moderate mitral valve regurgitation?
  • Can the adverse drug reactions caused by the modified drug therapy be non-inferior (clinically acceptable) to those of the traditional drug therapy? Participants will be assigned to either the Modified Drug Therapy Group (comprising angiotensin-converting enzyme inhibitor (ACE-I), beta-blockers, diuretics, potassium supplements, and spironolactone) or the Traditional Drug Therapy Group (diuretics and potassium supplements) based on personal preferences and clinical assessments by their attending physicians. They will undergo a one-year course of medication. Additionally, echocardiography, electrocardiograms, complete blood counts, biochemical tests, and measurements of N-terminal pro-brain natriuretic peptide (NT-proBNP) were conducted before the initiation of medication therapy and at 3 months, 6 months, and 12 months after treatment commencement.

Researchers will compare the Modified Drug Therapy Group and the Traditional Drug Therapy Group to see if the recurrence rate of moderate to severe mitral valve regurgitation, as assessed by echocardiography after 12 months of treatment, is lower in the former than in the latter.

03

Conditions studied

  • Congenital Mitral Insufficiency

Keywords

  • congenital heart disease
  • mitral regurgitation
  • drug therapy
04

Who can participate

Ages eligible
Up to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children under the age of 14 with moderate to severe mitral valve regurgitation, without contraindications for mitral valve repair, and without an immediate need for surgery.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • \< 14 years old
  • had not undertake mitral valve surgery before
  • moderate to severe mitral regurgitation

Exclusion criteria

Exclusion Criteria:

  • moderate to severe mitral regurgitation which concommitant with other cardiac malformation which can not be correct or can only perform palliative surgery
  • concommitant with mitral stenosis
  • ischemic mitral regurgitation (for example, concommitant with anomalous origin of coronary artery)
  • Barlow syndrome
  • dysplasia of mitral leaflet
  • complete/Partial endocardial cushion defect
  • common atrioventricular valve
  • atrioventricular common channel
  • cardiomyopathy
  • other mitral valve surgery
  • moderate to severe mitral regurgitation requires mitral valve surgery
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
122 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • Modified Drug Therapy Group

    Patient in this group will undergo a one-year course of medication, including Captopril(tablet, 0.3mg/kg, tid), Metoprolol(tablet, 0.2mg/kg, bid), Spironolactone(tablet, 2-4mg/kg, bid), Torsemide(tablet, 0.2-0.5mg/mg, bid), and Potassium Citrate(powder, 0.06g/kg, tid).

    Drug: Captopril Tablets · Drug: Metoprolol Oral Tablet · Drug: Spironolactone Tablets · Drug: Torsemide Tablets · Drug: Potassium citrate powder

  • the Traditional Drug Therapy Group

    Patient in this group will undergo a one-year course of medication, including Torsemide(tablet, 0.2-0.5mg/mg, bid) and Potassium Citrate(powder, 0.06g/kg, tid).

    Drug: Torsemide Tablets · Drug: Potassium citrate powder

Interventions

06

What researchers measure

Primary outcomes

  1. the recurrence rate of moderate to severe mitral valve regurgitation

    During follow-up visits, echocardiographic examination is conducted to measure the degree of mitral valve regurgitation. If it falls within the moderate to severe range, it is recorded as a recurrence.

    Time frame: after 12 months of treatment

Secondary outcomes

  1. Improvement in symptoms

    Based on patient and caregiver descriptions, if symptoms such as chest discomfort, shortness of breath, and delayed development show improvement following physical activity, it is recorded as an improvement in symptoms.

    Time frame: after 12 months of treatment

  2. Change in left ventricular ejection fraction

    Based on the echocardiogram, measurements are taken for left ventricular ejection fraction.

    Time frame: after 12 months of treatment

  3. Change in left ventricular end-diastolic diameter

    Based on the echocardiogram, measurements are taken for left ventricular end-diastolic diameter.

    Time frame: after 12 months of treatment

  4. NT-proBNP level

    The trend in NT-proBNP levels.

    Time frame: after 12 months of treatment

  5. Incidence rate of drug adverse reactions

    The incidence of abnormalities in complete blood count, electrolytes, liver and kidney function, and cardiac enzymes.

    Time frame: after 12 months of treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Aug 2024, 28 months after the start.

Of 178 non-industry observational studies under Heart Defects, Congenital, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 83. This study's planned 28 months is below that.

Counting every sponsor, half of 185 studies reached it within 44 months; a quarter within 17 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2023
First posted
Sep 14, 2023
StartActual
Apr 1, 2022
Primary completionEst.
Aug 9, 2024
CompletionEst.
Dec 31, 2024
Last update
Sep 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06037434
Collaborators
Shanghai Children's Medical Center, Chinese Academy of Medical Sciences, Fuwai Hospital, Guangzhou Women and Children's Medical Center, Children's Hospital of Chongqing Medical University
Responsible party
Shoujun Li (Director of Congenital Heart Surgery Center, China National Center for Cardiovascular Diseases) — Principal investigator
First posted
Sep 14, 2023
Start date
Apr 1, 2022
Primary completion
Aug 9, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Sep 15, 2023

Study contacts

Kai Ma, PhD
Contact
drmakaifw@yahoo.com
+86 15901428497
Zheng Dou, PhD
Contact
drdouzheng@163.com
+86 18810673618
Shoujun Li, MD
study chair · Chinese Academy of Medical Sciences, Fuwai Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion